DBVT DBV Technologies S.A.

5.52
-0.06  -1%
Previous Close 5.58
Open 5.5
52 Week Low 1.35
52 Week High 7.38
Market Cap $606,496,608
Shares 109,872,574
Float 109,768,479
Enterprise Value $483,535,580
Volume 27,314
Av. Daily Volume 52,526
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
Viaskin Peanut - (PREQUAL)
Healthy volunteers
Phase 1
Phase 1
Phase 1 trial initiated 2Q 2021.
Viaskin Peanut
Peanut allergy - ages 4 to 11 years
CRL
CRL
CRL issued August 4, 2020
Viaskin Peanut (EPITOPE)
Peanut allergy - ages 1 to 3 years
Phase 3
Phase 3
Phase 3 (Part B) enrolment expectations due 2H 2020.
Viaskin Milk
Cow’s milk protein allergy (CMPA)
Phase 1/2
Phase 1/2
Phase 1/2 data released February 2018.

Latest News

  1. Monthly information regarding the total number of voting rights and

    total number of shares of the Company as of September 30, 2021

     

    (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

     

    Market : NYSE Euronext Paris

    ISIN Code: FR 0010417345 



    Date

    Total number of shares Total number of voting rights
    09/30/202155,011,687

    Total gross of voting rights: 55,011,687



    Total net* of voting rights: 54,936,287

    * Total net = total number of voting rights attached to shares – shares without voting rights

     

     

     

     

    Attachment


    Primary Logo

    Monthly information regarding the total number of voting rights and

    total number of shares of the Company as of September 30, 2021

     

    (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

     

    Market : NYSE Euronext Paris

    ISIN Code: FR 0010417345 





    Date



    Total number of shares Total number of voting rights
    09/30/202155,011,687



    Total gross of voting rights: 55,011,687







    Total net* of voting rights: 54,936,287



    * Total net = total number of voting rights attached to shares – shares without voting rights

     

     

     

     

    Attachment



    Primary Logo

    View Full Article Hide Full Article
  2. Monthly information regarding the total number of voting rights and

    total number of shares of the Company as of August 31, 2021

    (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

     

    Market : NYSE Euronext Paris

    ISIN Code: FR 0010417345



    Date

    Total number of shares Total number of voting rights
    08/31/202155,011,687

    Total gross of voting rights: 55,011,687



    Total net* of voting rights: 54,963,687

    * Total net = total number of voting rights attached to shares – shares without voting rights

     

     

     

     

    Attachment


    Primary Logo

    Monthly information regarding the total number of voting rights and

    total number of shares of the Company as of August 31, 2021

    (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

     

    Market : NYSE Euronext Paris

    ISIN Code: FR 0010417345





    Date



    Total number of shares Total number of voting rights
    08/31/202155,011,687



    Total gross of voting rights: 55,011,687







    Total net* of voting rights: 54,963,687



    * Total net = total number of voting rights attached to shares – shares without voting rights

     

     

     

     

    Attachment



    Primary Logo

    View Full Article Hide Full Article
  3. Montrouge, France, August 31, 2021

    DBV Technologies to Participate at Upcoming Investor Conferences

    DBV Technologies (GREY:DBVTF), a clinical-stage biopharmaceutical company, today announced that DBV Technologies' senior management team will participate in upcoming virtual investor conferences in September.

    Goldman Sachs Eleventh Annual Biotech Symposium
    Company management will participate in virtual investor meetings on September 7, 2021.

    Citi's 16th Annual BioPharma Virtual Conference
    Company management will participate in virtual investor meetings on September 8, 2021.

    H.C. Wainwright 23rd Annual Global Investment Conference
    The pre-recorded fireside chat will be available on demand starting September 13, 2021 at 7:00 AM ET for the duration…

    Montrouge, France, August 31, 2021

    DBV Technologies to Participate at Upcoming Investor Conferences

    DBV Technologies (GREY:DBVTF), a clinical-stage biopharmaceutical company, today announced that DBV Technologies' senior management team will participate in upcoming virtual investor conferences in September.

    Goldman Sachs Eleventh Annual Biotech Symposium

    Company management will participate in virtual investor meetings on September 7, 2021.

    Citi's 16th Annual BioPharma Virtual Conference

    Company management will participate in virtual investor meetings on September 8, 2021.

    H.C. Wainwright 23rd Annual Global Investment Conference

    The pre-recorded fireside chat will be available on demand starting September 13, 2021 at 7:00 AM ET for the duration of the conference.

    A webcast of the fireside chat will be available on the Investors & Media section of the Company's website: https://www.dbv-technologies.com/investor-relations/

    A replay of the fireside chat will also be available on DBV Technologies' website after the event.

    About DBV Technologies

    DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Summit, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (NYSE:DBV, ISIN code: FR0010417345))), part of the SBF120 index, and the Company's ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (NASDAQ:DBVT).

    Investor Contact

    Anne Pollak

    DBV Technologies

    +1 857-529-2363

    anne.pollak@dbv-technologies.com

    Media Contact

    Angela Marcucci

    DBV Technologies

    +1 646-842-2393

    angela.marcucci@dbv-technologies.com 

    Attachment



    Primary Logo

    View Full Article Hide Full Article
  4. GARDEN CITY, N.Y., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced the appointment of Douglas Larson as Chief Financial Officer, succeeding Douglas Beck effective September 1, 2021. Mr. Beck will remain a consultant to the Company and is expected to work closely with Mr. Larson and the Beyond Air leadership team to ensure a seamless transition of CFO responsibilities.

    Douglas Larson joins Beyond Air with over 20 years of international…

    GARDEN CITY, N.Y., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ:XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced the appointment of Douglas Larson as Chief Financial Officer, succeeding Douglas Beck effective September 1, 2021. Mr. Beck will remain a consultant to the Company and is expected to work closely with Mr. Larson and the Beyond Air leadership team to ensure a seamless transition of CFO responsibilities.

    Douglas Larson joins Beyond Air with over 20 years of international and operational financial leadership experience. Recently he served as Vice President, Finance and Head of Global Controlling at DBV Technologies, Inc. (NASDAQ:DBVT), a global clinical stage biopharmaceutical company headquartered in France, from 2017 to 2020. Prior to DBV, Mr. Larson served as the Chief Financial Officer of The Scotts Miracle-Gro Company's International division, based in Lyon, France from 2001 to 2015. Mr. Larson has a deep knowledge of performance management, supply chain finance, forecasting and business modeling, and defining and executing strategic and financial goals for companies in various stages of development across a diverse geographic footprint.

    "On behalf of the Board of Directors and the entire company, I want to thank Mr. Beck for his commitment to Beyond Air and continued support. Since joining in 2018, Mr. Beck has been instrumental to our success, leading with a forward-thinking mindset and establishing the financial foundation for our future development and growth. He leaves the Company in a strong cash position, and I personally want to thank him for his contributions and wish him the best in his future endeavors," commented Steve Lisi, Chairman and Chief Executive Officer of Beyond Air. "This transition comes at a time of tremendous momentum for Beyond Air, and I am excited to welcome Douglas Larson to effectively guide the Company through our transition to a commercial stage entity."

    In connection with the appointment of Mr. Larson, the Company granted Mr. Larson an inducement stock option award (the "Inducement Option") as an inducement material to Mr. Larson's entering into employment with the Company in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The Inducement Option is being granted effective as of September 1, 2021 and is exercisable for the purchase of 75,000 shares of the Company's common stock, at an exercise price equal to the last reported sale price on Nasdaq on September 1, 2021. The Inducement Option grant was approved by the independent compensation committee of the Board in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The Inducement Option has a ten-year term and will vest over a four-year period, with 25% of the shares underlying the stock option award vesting on the first anniversary of the date of grant and annually thereafter in three equal installments, subject to Mr. Larson's continued service with the Company through the applicable vesting dates. The Inducement Option is subject to the terms and conditions of the Company's 2013 Equity Incentive Plan.

    About Beyond Air, Inc.

    Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit®, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs for the potential treatment of a variety of pulmonary diseases. The LungFit® can generate up to 400 ppm of NO, for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its revolutionary LungFit® for clinical trials for the treatment of severe lung infections such as acute viral pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.

    Forward Looking Statements

    Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipates," "expects," "intends," "impacts," "plans," "projects," "believes," "estimates," "likely," "goal," "assumes," "targets" and similar expressions and/or the use of future tense or conditional constructions (such as "will," "may," "could," "should" and the like) constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements do not relate strictly to historical or current matters. Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including risks related to: our approach to discover and develop novel drugs, which is unproven and may never lead to efficacious or marketable products; our ability to fund and the results of further pre-clinical and clinical trials; obtaining, maintaining and protecting intellectual property utilized by our products; our ability to enforce our patents against infringers and to defend our patent portfolio against challenges from third parties; our ability to obtain additional funding to support our business activities; our dependence on third parties for development, manufacture, marketing, sales, and distribution of products; the successful development of our product candidates, all of which are in early stages of development; obtaining regulatory approval for products; competition from others using technology similar to ours and others developing products for similar uses; our dependence on collaborators; our short operating history and other risks identified and described in more detail in the "Risk Factors" section of the Company's most recent Annual Report on Form 10-K and other filings with the SEC, all of which are available on our website. We undertake no obligation to update, and we do not have a policy of updating or revising, these forward-looking statements, except as required by applicable law.

    CONTACTS:

    Maria Yonkoski, Head of Investor Relations

    Beyond Air, Inc.

    Myonkoski@beyondair.net

    Corey Davis, Ph.D.

    LifeSci Advisors, LLC

    Cdavis@lifesciadvisors.com

    (212) 915-2577



    Primary Logo

    View Full Article Hide Full Article
  5. Monthly information regarding the total number of voting rights and

    total number of shares of the Company as of July 31, 2021

    (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

    Market : NYSE Euronext Paris

    ISIN Code: FR 0010417345



    Date

    Total number of shares Total number of voting rights
    07/31/202155,011,687

    Total gross of voting rights: 55,011,687



    Total net* of voting rights: 54,942,087

     

    * Total net = total number of voting rights attached to shares – shares without voting rights

     

     

     

     

    Attachment


    Primary Logo

    Monthly information regarding the total number of voting rights and

    total number of shares of the Company as of July 31, 2021

    (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)

    Market : NYSE Euronext Paris

    ISIN Code: FR 0010417345





    Date



    Total number of shares Total number of voting rights
    07/31/202155,011,687



    Total gross of voting rights: 55,011,687







    Total net* of voting rights: 54,942,087



     

    * Total net = total number of voting rights attached to shares – shares without voting rights

     

     

     

     

    Attachment



    Primary Logo

    View Full Article Hide Full Article
View All DBV Technologies S.A. News